Indeed, by integrating multi-targeting strategies via the T1E ligand, enhanced persistence via 4αβ signaling, and immune modulation via NK cell recruitment, pan-ErbB-targeted T4 immunotherapy represents a novel and promising approach to overcoming HNSCC resistance to conventional treatments [80, 93, 94]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.